Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Next Previous
X
Search
Trial Profile

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulixertinib (Primary)
  • Indications Colorectal cancer; Gallbladder cancer; Gastrointestinal cancer; Glioblastoma; Head and neck cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Sponsors BioMed Valley Discoveries

    • Most Recent Events

    • 03 Jan 2021 Results assessing dAEs in patients treated with ulixertinib and analyze the correlation between dAEs and tumor responses, published in the Investigational New Drugs.
    • 19 Sep 2018 Status changed from active, no longer recruiting to completed.
    • 17 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Feb 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top